CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

Kaspers GJL, van Hamel M, Abrahamsson J, Arad-Cohen N, Benedictus R, Scheidegger N, Castillo L, Ka Leung Cheuk D, Costa V, Duong Y, Fernandez Navarro JM, Fogelstrand L, Goemans BF, Ishimaru S, Jonsson OG, Juul-Dam KL, Karu M, Koedijk JB, Kovalova Z, De Moerloose B, Munthe-Kaas MC, Palmu S, Pasauliene R, Tierens A, van Tinteren H, Turkiewicz D, Valerio DG, Wijnen N, Zwaan CM, Pronk CJ

Open source

DOI: 10.1186/s13063-026-09855-5
Published: 2026 Jun 20
Container: Trials
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s13063-026-09855-5,
  title = {CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.},
  author = {Kaspers GJL and van Hamel M and Abrahamsson J and Arad-Cohen N and Benedictus R and Scheidegger N and Castillo L and Ka Leung Cheuk D and Costa V and Duong Y and Fernandez Navarro JM and Fogelstrand L and Goemans BF and Ishimaru S and Jonsson OG and Juul-Dam KL and Karu M and Koedijk JB and Kovalova Z and De Moerloose B and Munthe-Kaas MC and Palmu S and Pasauliene R and Tierens A and van Tinteren H and Turkiewicz D and Valerio DG and Wijnen N and Zwaan CM and Pronk CJ},
  year = {2026},
  journal = {Trials},
  doi = {10.1186/s13063-026-09855-5},
  url = {https://doi.org/10.1186/s13063-026-09855-5}
}

RIS

TY  - JOUR
TI  - CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.
AU  - Kaspers GJL
AU  - van Hamel M
AU  - Abrahamsson J
AU  - Arad-Cohen N
AU  - Benedictus R
AU  - Scheidegger N
AU  - Castillo L
AU  - Ka Leung Cheuk D
AU  - Costa V
AU  - Duong Y
AU  - Fernandez Navarro JM
AU  - Fogelstrand L
AU  - Goemans BF
AU  - Ishimaru S
AU  - Jonsson OG
AU  - Juul-Dam KL
AU  - Karu M
AU  - Koedijk JB
AU  - Kovalova Z
AU  - De Moerloose B
AU  - Munthe-Kaas MC
AU  - Palmu S
AU  - Pasauliene R
AU  - Tierens A
AU  - van Tinteren H
AU  - Turkiewicz D
AU  - Valerio DG
AU  - Wijnen N
AU  - Zwaan CM
AU  - Pronk CJ
PY  - 2026
JO  - Trials
DO  - 10.1186/s13063-026-09855-5
UR  - https://doi.org/10.1186/s13063-026-09855-5
ER  -

APA

GJL, K., M, V. H., J, A., N, A., R, B., N, S., L, C., D, K. L. C., V, C., Y, D., JM, F. N., L, F., BF, G., S, I., OG, J., KL, J., M, K., JB, K., Z, K., B, D. M., MC, M., S, P., R, P., A, T., H, V. T., D, T., DG, V., N, W., CM, Z., & CJ, P. (2026). CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.. Trials. https://doi.org/10.1186/s13063-026-09855-5

Source records

pubmed · retrieved 2026-09-26T05:25:22.665Z